Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


All  |  2013  |  2012  |  2011  |  2010  |  2009  |  2008  |  2007  |  2006  |  2005  

Date Title
6/10/2013 Stemline Therapeutics’ SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
5/31/2013 Stemline Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
5/30/2013 Stemline Therapeutics Announces Presentations at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
5/23/2013 Stemline Therapeutics Announces Exercise of Option to Purchase Additional Shares
5/22/2013 Stemline Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
5/16/2013 Stemline Therapeutics Prices $60 Million Public Offering of Common Stock
4/25/2013 Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013
4/8/2013 Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, Japan
4/1/2013 Stemline Therapeutics Reports Year-End 2012 Financial Results
3/12/2013 Stemline Therapeutics to Present at the 25th Annual Roth Conference on March 20, 2013
2/27/2013 Stemline Therapeutics to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
2/12/2013 Stemline Therapeutics to Present at Leerink Swann and Company Global Healthcare Conference
2/7/2013 Stemline Therapeutics, Inc. to Present at BIO CEO & Investor Conference on February 11th
1/31/2013 Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering
1/29/2013 Stemline Therapeutics, Inc. Announces Exercise of Over-Allotment Option
1/28/2013 Stemline Therapeutics, Inc. Announces Pricing of Initial Public Offering of 3,317,644 Shares of Common Stock
1/7/2013 Stemline Therapeutics’ Lead Clinical Candidate, SL-401, Induces Another Complete Response in a Patient with a Drug-Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
12/7/2012 Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin’s Lymphoma at the 54th Annual Meeting of the American Society of Hematology (ASH)
11/8/2012 Stemline Therapeutics’ Lead Clinical Candidate SL-401 Induces a Complete Response in a Patient with a Drug-Refractory Plasmacytoid Dendritic Cell Neoplasm
4/18/2012 Stemline Therapeutics Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association of Cancer Research (AACR)
4/3/2012 Stemline Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3/15/2012 Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to its Board of Directors
1/9/2012 Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
12/12/2011 Stemline Therapeutics, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
12/8/2011 Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
6/2/2011 Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting
3/9/2011 Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia
2/23/2011 Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh
12/1/2010 Stemline Therapeutics, Inc. Announces Presentations of SL-401 Clinical and Pre-Clinical Efficacy at the 52nd Annual Meeting of the American Society of Hematology (ASH)
12/4/2009 Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
11/30/2009 Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of MD Anderson Cancer Center
4/9/2008 Stemline Therapeutics raises $12.5 million
3/7/2007 Stemline Therapeutics In-Licenses Phase I Oncology Compound
9/29/2006 Stemline is awarded a National Institutes of Health STTR grant
1/17/2005 Stemline licenses high throughput drug discovery technology from University of Cambridge

 

Copyright 2013 - Stemline Therapeutics, Inc. All rights reserved
Stemline